^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIRLET7E (MicroRNA Let-7e)

    i
    Other names: MIRLET7E, MicroRNA Let-7e, Hsa-Let-7e-3p, Hsa-Let-7e-5p, Hsa-Let-7e, MIRNLET7E, Hsa-Let-7-P1b_pre, MIMAT0000066, MIMAT0004485, MI0000066, RF00027, Let-7e, LET7E
    Associations

    News

    Trials
    14d
    Profiles of microRNAs in Patients with Advanced Breast Cancer Who are Chemoresistant or Chemosensitive to Fluorouracil, Adriamycin, and Cyclophosphamide Treatment. (PubMed, Asian Pac J Cancer Prev)
    Therefore, these findings suggest that miRNAs may serve as predictive biomarkers and potential therapeutic targets in the management of breast cancer.
    Journal
    |
    MIR152 (MicroRNA 152) • MIR27A (MicroRNA 27a) • MIR424 (MicroRNA 424) • MIR195 (MicroRNA 195) • MIR20A (MicroRNA 20a) • MIR214 (MicroRNA 214) • MIR222 (MicroRNA 222) • MIRLET7E (MicroRNA Let-7e)
    |
    5-fluorouracil • doxorubicin hydrochloride • cyclophosphamide
    1m
    SPACA6-hosted miR-99b~125a~let-7e cluster shapes melanoma resistance by modulating mTOR-mediated immunosuppression. (PubMed, Front Immunol)
    Together, these findings identify the SPACA6-hosted miR-99b~125a~let-7e cluster as a regulator of BRAF/MEK inhibitor resistance through promotion of tumor survival and of an immunosuppressive microenvironment. Targeting this miRNA cluster may provide novel therapeutic opportunities to overcome drug resistance in metastatic melanoma.
    Journal
    |
    IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCL2 (Chemokine (C-C motif) ligand 2) • MIR125A (MicroRNA 125a) • MIR99B (MicroRNA 99b) • MIRLET7E (MicroRNA Let-7e) • NR6A1 (Nuclear Receptor Subfamily 6 Group A Member 1)
    4ms
    In-Silico discovery of Pediatric Acute-Myeloid-Leukemia (pAML) causing druggable molecular signatures highlighting their pathogenetic processes and therapeutic agents through single-cell RNA-Seq profile analysis. (PubMed, PLoS One)
    Subsequently, three potential therapeutic candidates (IRINOTECAN HYDROCHLORIDE, IMATINIB and IBRUTINIB) were disclosed through an integrative strategy combining molecular docking, drug-likeness, ADME/T, and DFT analyses. Molecular dynamics (MD) simulation studies for the top three drug-target complexes indicated the stability of complexes. Thus, the findings potentially offer valuable insights for pAML pathogenesis and effective therapeutic candidates for pAML patients.
    Journal
    |
    TP53 (Tumor protein P53) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • MCL1 (Myeloid cell leukemia 1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • CD4 (CD4 Molecule) • GATA2 (GATA Binding Protein 2) • FOXC1 (Forkhead Box C1) • MIR15A (MicroRNA 15a) • MIRLET7E (MicroRNA Let-7e) • RELA (RELA Proto-Oncogene) • SOD2 (Superoxide Dismutase 2)
    |
    Imbruvica (ibrutinib) • imatinib • irinotecan
    4ms
    Discovery of KMT5A repressed miR-99b cluster with potential to restore chemotherapy sensitivity in gastric cancer by regulating mitochondrial Complex II and affecting OXPHOS. (PubMed, Pharmacol Res)
    Findings from GC cells, organoids and PDX models demonstrated that overexpression of the miR-99b cluster sensitized GC to cisplatin, likely through its inhibitory effects on mitochondrial respiratory function, particularly OXPHOS...Moreover, elevated KMT5A expression and decreased miR-125a-5p expression indicated both poorer prognosis and chemo-resistance in patients with GC. This study highlights the multifaceted roles of the miR-99b cluster in GC and offers novel perspectives for the development of innovative therapeutics aimed at overcoming chemoresistance and enhancing treatment efficacy for GC patients.
    Journal
    |
    SDHC (Succinate Dehydrogenase Complex Subunit C) • KMT5A (Lysine Methyltransferase 5A) • MIR125A (MicroRNA 125a) • MIR99B (MicroRNA 99b) • MIRLET7E (MicroRNA Let-7e)
    |
    cisplatin
    5ms
    MINING THE CELLMINER DATABASE TO IDENTIFY SHARED BIOMARKERS OF 5-FU AND OXALIPLATIN RESPONSE. (PubMed, Georgian Med News)
    This integrative analysis identify potential biomarkers associated with 5-FU and Oxaliplatin response, nominating ALDH9A1, FERMT3, NT5E, HIF1A, and specific microRNAs as resistance biomarkers, while GRIN1, MTHFD2, and miR-7 emerge as sensitizers. Importantly, repurposing opportunities were identified, with statins and kinase inhibitors showing context-dependent associations that may help overcome resistance. These findings may provide a framework for potential biomarkers guided therapy optimization and may inform rational combination strategies in colorectal cancer.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto) • COL1A1 (Collagen Type I Alpha 1 Chain) • MIR7 (MicroRNA 7) • FERMT3 (FERM Domain Containing Kindlin 3) • LRIG2 (Leucine Rich Repeats And Immunoglobulin Like Domains 2) • DUSP1 (Dual Specificity Phosphatase 1) • MIR22 (MicroRNA 22) • MIR30A (MicroRNA 30a) • MIRLET7E (MicroRNA Let-7e) • MTHFD2 (Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 2)
    |
    5-fluorouracil • oxaliplatin
    5ms
    Diagnostic and prognostic potential of microRNA profiles in endometrioid endometrial cancer. (PubMed, Sci Rep)
    We showed that miRNAs have good diagnostic sensitivity for identifying EEC and EC grading. In addition, miRNA improved the ability to discriminate between ECs of different grades.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • PTEN (Phosphatase and tensin homolog) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MIR200B (MicroRNA 200b) • MIR21 (MicroRNA 21) • MIR200C (MicroRNA 200c) • MIR429 (MicroRNA 429) • MIR30B (MicroRNA 30b) • MIR324 (MicroRNA 324) • MIR543 (MicroRNA 543) • MIR96 (MicroRNA 96) • Let-7c (MicroRNA Let-7c) • MIR126 (MicroRNA 126) • MIR141 (MicroRNA 141) • MIR182 (MicroRNA 182) • MIR18A (MicroRNA 18a) • MIR129 (MicroRNA 129) • MIR129-2 (MicroRNA 129-2) • MIR130A (MicroRNA 130a) • MIR181B1 (MicroRNA 181b-1) • MIR183 (MicroRNA 183) • MIR203A (MicroRNA 203a) • MIR205 (MicroRNA 205) • MIR217 (MicroRNA 217) • MIR30C • MIRLET7E (MicroRNA Let-7e)
    5ms
    DNA Damage and Repair in Ovarian Cancer: Focus on MicroRNAs. (PubMed, Cancers (Basel))
    We also discuss miRNAs (such as miR-519a-3p, let-7e, miR-216b), which affect responses to OvCa therapy by targeting PARP1 (Poly(ADP-Ribose) Polymerase-1). Finally, we also discuss why, despite the identification of multiple miRNAs capable of regulating DNA repair genes, as well as those involved in the response to therapy, no miRNA-based drugs have been approved for OvCa treatment in clinics.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MIR193B (MicroRNA 193b) • DDB2 (Damage Specific DNA Binding Protein 2) • MIR328 (MicroRNA 328) • MIR148B (MicroRNA 148b) • MIR203A (MicroRNA 203a) • MIR214 (MicroRNA 214) • MIRLET7E (MicroRNA Let-7e) • RNF8 (Ring Finger Protein 8)
    |
    Lynparza (olaparib)
    8ms
    Using Multiomics and Machine Learning: Insights into Improving the Outcomes of Clear Cell Renal Cell Carcinoma via the SRD5A3-AS1/hsa-let-7e-5p/RRM2 Axis. (PubMed, ACS Omega)
    Drug sensitivity assays identified axitinib and sorafenib as potential SRD5A3-AS1 inhibitors and dasatinib and fulvestrant as RRM2 inhibitors. The molecular docking results confirmed the stability of the binding of RRM2 to dasatinib and fulvestrant, suggesting that these drugs are promising for therapeutic applications in ccRCC.
    Journal
    |
    CD8 (cluster of differentiation 8) • MIF (Macrophage Migration Inhibitory Factor) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • MIRLET7E (MicroRNA Let-7e)
    |
    dasatinib • sorafenib • fulvestrant • axitinib
    9ms
    A 3-miRNA signature for noninvasive breast cancer detection. (PubMed, Semin Oncol)
    Similarly, significant prognostic clinical characteristics were observed for these miRNAs. Overall, we have identified and validated a novel and proficient signature biomarker in serum of BC patients consisting of 3 miRNAs.
    Journal
    |
    MIR887 (MicroRNA 887) • MIRLET7E (MicroRNA Let-7e)
    9ms
    MicroRNA-371-373 cluster extracellular vesicle-based communication in testicular germ cell tumors. (PubMed, Cell Commun Signal)
    TGCT patient samples presented high levels of EV-derived miR-371-373, except for the teratoma samples. We conclude that a significant portion of the circulating miR-371-373 cluster used as a TGCT biomarker in the clinic is secreted into EVs, and that this cluster and the let-7 family of microRNAs may be related with TGCT intercellular communication and differentiation.
    Journal
    |
    MIRLET7E (MicroRNA Let-7e)
    10ms
    A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma. (PubMed, SAGE Open Med)
    Based on this evidence, exploring circulating miRNAs as a potential noninvasive biomarker for multiple myeloma represents a noteworthy advancement. This is attributed to the abundance of miRNAs in plasma or serum, which exhibits remarkable stability against enzymatic degradation.
    Review • Journal
    |
    MIR34A (MicroRNA 34a-5p) • MIR1246 (MicroRNA 1246) • MIR130A (MicroRNA 130a) • MIR15A (MicroRNA 15a) • MIR19A (MicroRNA 19a) • MIR20A (MicroRNA 20a) • MIR483 (MicroRNA 483) • MIRLET7E (MicroRNA Let-7e)
    |
    bortezomib
    11ms
    Elucidating the Role of LINC01980 in Laryngeal Cancer: From Expression Profiling to Regulatory Network Prediction. (PubMed, Int J Mol Cell Med)
    This study provides insights into LINC01980's role in LSCC and suggests its potential as a diagnostic biomarker and therapeutic target. Further research is warranted to elucidate the precise molecular mechanisms of LINC01980 in LSCC progression.
    Journal
    |
    MMP9 (Matrix metallopeptidase 9) • MIRLET7E (MicroRNA Let-7e)